Clinical Review of Shanchol™ (a WHO pre-qualified oral cholera vaccine)  by D’Cor, N.A. & Patnaik, B.N.
17th International Congress on Infectious Diseases / International Journal of Infectious Diseases 45S (2016) 1–477 417
Type: Poster Presentation
Final Abstract Number: 43.152
Session: Poster Session III
Date: Saturday, March 5, 2016
Time: 12:45-14:15
Room: Hall 3 (Posters & Exhibition)
A quick method to determine the best threshold
level for universial vacciantion when there is an
outbreak of Japanese Encephalitis
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Background: Japanese Encephalitis (JE) has an increasing trend
inmanyparts of theworld, especially the globalwarming facilitates
the perpetuation of the vectors, mosquitoes. Although JE vaccina-
tion is a proven useful control strategy, at the same time it has a
not low associated complication rate. What is the best time to opt
for universal vaccination need a careful balance.
Methods & Materials: A risk verus beneﬁt approach is used
to determine the best time to opt for universal JE vaccination,
using Hong Kong as an example. Two sources of information are
used to determine the case loads / endemicity of JE (as a proxy to
estimate the potential beneﬁt for vaccination): (1) Seroprevalence
in different population subgroups; (2) Surveillance information
from the Government Disease Control Centre under the WHO IHR.
Two sources of information are used to assess the potential risks
for vaccination: (1) Complication rate for JE vaccination based on
pharmaceutical companies’ data; (2) Acceptability, knowledge and
attitude of JE vaccination in the public
Results: The baseline case load of JE in Hong Kong is not
high. However, certain subgroups are at high risk (e.g. elderly) as
reﬂected by a higher seroprevalence rate. Universal vaccination
may be justiﬁed only if the annual incidence is higher than the
damage potentially caused by the vaccination itself.
Conclusion: There is a need to review the surveillance process
since updated data is the crux for an accurate assessment. Even
if there is an universal JE vaccination program, the responsible
authority (e.g. government) has to address the concern from the
public in order to achieve a satisfactory coverage for signiﬁcant
community protection.
http://dx.doi.org/10.1016/j.ijid.2016.02.889
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Background: Cholera caused by Vibrio cholerae of the O1 or
O139 serogroup is an important cause of severe dehydrating diar-
rhea in adults and children. It continues to be a major global
health problem. The WHO estimates that 3-5 million cases and
100,000–130,000 deaths occur per year globally, predominantly in
Asia and Africa.
The WHO recommends that in cholera-endemic countries, vac-
cination should be used as an additional tool to control cholera
along with longer term interventions of improving water and san-
itation. It recommends pre-emptive vaccination to help prevent
potential outbreaks or the spread of current outbreaks.
ShancholTM is a ready-to-use killed bivalent (O1 and O139)
whole-cell oral cholera vaccine administered as 2 doses 14 days
apart in individuals aged 1 year and above. There is no need for
buffer or water for its administration. It is currently licensed in
India and 17 other countries in Asia, Africa and Latin America. It
is prequaliﬁed for international use by the WHO. The vaccine is the
basis for the WHO stockpile which is used to help control cholera
epidemics.
Methods&Materials: Clinical analysis of safety, immunogenic-
ity and efﬁcacy studies of ShancholTM
Results: Overall, ∼66,000 doses have been administered to sub-
jects during the clinical development of the vaccine. ShancholTM
was observed to provide sustained protective efﬁcacy level of 65%
for at least 5 years in a clinical trial conducted in over 69,000 sub-
jects in India. The herd effect conferred by ShancholTM was evident
with minimum vaccine coverage of 38% and was sustained for at
least 3 years.
Safety and immunogenicity clinical trials conducted in India,
Bangladesh, Ethiopia, Philippines andHaiti showed that thevaccine
is safe and provides good immune responses in different endemic
populations.
Results from a clinical study showed that ﬂexible dosing sched-
ule of ShancholTM as 2 doses 14 to 28 days apart is possible. A
modeling study observed that single-dose vaccinationmayprevent
more deaths during outbreaks than 2-dose vaccination.
ShancholTM was alsoobserved tobehighly effective inmass vac-
cination campaigns inGuinea,Haiti, Odisha (India) andBangladesh.
Conclusion: ShancholTM vaccine is safe and effective for con-
trol of cholera in endemic countries
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